C4 Therapeutics Enters Clinical Trial Collaboration with Pfizer for Multiple Myeloma Drug Combination

C4 Therapeutics, Inc.

C4 Therapeutics and Pfizer signed a clinical trial collaboration and supply agreement for elranatamab and cemsidomide.
Pfizer will supply elranatamab (ELREXFIO) at no cost for a Phase 1b trial in relapsed/refractory multiple myeloma.
The Phase 1b trial will evaluate cemsidomide, dexamethasone, and elranatamab as second-line or later therapy.
Trial expected to start in Q2 2026; C4 Therapeutics sponsors and conducts the trial.
C4 Therapeutics CEO noted potential to improve outcomes and combine with a growing standard-of-care bispecific.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.